Skip to Content
Click
here
to view the Site Map
Home
|
Sitemap
|
Contact DCTD
Search this site
Cancer Therapy Evaluation Program (CTEP)
Introduction
Major Ongoing Initiatives
Significant Ongoing Clinical Trials
Current Funding Opportunities
Partnerships and Collaborations
Scientific Advances
Tools, Products, and Resources
DCTD Programs
Cancer Diagnosis Program
Cancer Imaging Program
Cancer Therapy Evaluation Program
Developmental Therapeutics Program
Radiation Research Program
Translational Research Program
Biometric Research Branch
Office of Cancer Complementary and Alternative Medicine
Last Updated:
04/25/2012
SIGNIFICANT ONGOING CLINICAL TRIALS
Early Phase Trials
Early Phase Trials Targeting Unique Molecular Aberrations in Tumors
Definitive, Late Phase Trials
A Randomized, Double-Blind Phase 3 Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
Phase 3 Study of R-CHOP versus R-Dose-Adjusted-Epoch with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Trial Assessing Individualized Options for Treatment (TAILORx) in the Adjuvant Setting for Women with Breast Cancer
Phase 3 Trial of Temozolomide and Radiotherapy Plus Bevacizumab for Newly Diagnosed Glioblastoma Tumors
Incorporating Novel Agents into the Treatment of Pediatric Acute Lymphoblastic Leukemia
Phase 3 Treatment Trials in Early Stage Non-Small Cell Lung Cancer Will Assess the Clinical Benefit of Bevacizumab as Part of Adjuvant Therapy and Surgical Resection Techniques
Phase 3 Trial in Advanced Non-Small Cell Lung Cancer Will Assess FDG-PET/CT as Predictive Marker of Response and Patient Outcome
Phase 3 Trial Evaluating Radiotherapy to the Pelvic Lymph Nodes with Short-Term Androgen Deprivation in Prostate Cancer Patients with a Rising Prostate-Specific Antigen after Radical Prostatectomy
International Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study—The ALTTO Study